Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Novo Nordisk’S OZEMPIC Approval Heat Up The Chronic Kidney Disease Therapeutic Market | Delveinsight
Novo Nordisk's blockbuster medication has gained another label expansion, now authorized for treating chronic kidney disease. New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's ...
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Diabetes giant Novo Nordisk has opened a new front in ... in phase 2 to reduce the risk of cardiovascular events in chronic kidney disease (CKD) patients with atherosclerosis.
a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to US$1.3 billion. However, in June 2024 Novo Nordisk said it was ...
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results